Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Lifestyle

"Suppress with medication and target with immunity"... Neogen Logic Develops Personalized Immunotherapy Vaccine Targeting Ovarian Cancer Recurrence

SCL Science(246960) Subsidiary Neogen Logic is pursuing a treatment strategy that combines an ovarian cancer drug with a patient-tailored cancer vaccine to delay recurrence. This approach involves sup…
  • 2026-11-18 08:07:02
  • KIM JI-WAN
Lifestyle

Park Woong-yang, CEO of GENINUS Inc.: “AI-Driven New Drug Development Evolves by Learning from Failure”

“It’s because AI itself doesn’t know when it’s wrong.”Park Woong-yang, CEO of GENINUS Inc. and a professor at Samsung Seoul Hospital, explained the reason for combining AI-driven new drug development …
  • 2026-11-18 07:26:03
  • KIM JI-WAN
Technology

Director Jang Jin-seok: “EarlyTec-B Will Alleviate the Burden of Cystoscopy and Become a New Option” [Expert Insight]

“I believe EarlyTec-B has the potential to largely replace existing bladder cancer tumor marker tests. It could also serve as a new testing option for patients with hematuria who are hesitant about un…
  • 2026-11-17 11:02:02
  • NA EUN-KYUNG
Technology

AriBio Lab Soars...HLB Therapeutics Hits Lower Limit [K-Bio Pulse]

Korean pharmaceutical and biotech stocks saw sharply divergent performance on November 16 as investors reacted to clinical news. Corestem ChemOn hit the daily upper limit after clarifying its U.S. app…
  • 2026-11-17 10:02:03
  • Kim Seung-kwon
Technology

ARIBIOLAB and CoaStemChem Soar Together… HLB Therapeutics Falls on Phase 3 Trial Failure [Bio Spotlight]

On the 16th, the domestic pharmaceutical and biotech sector saw a stark divergence in stock performance depending on clinical developments.CORESTEMCHEMON(166480), which clarified the U.S. approval pat…
  • 2026-11-17 10:02:02
  • Kim Seung-kwon
Lifestyle

[Exclusive] Company Hints at Legal Battle with Largest Shareholder… Key Issue: Abolition of Supermajority Voting [OSCOTEC Inc. Dispute, Part 2]

September 22. With the Chuseok holiday just two days away, many people were buzzing with anticipation for the long weekend. However, the largest shareholder, standing in the public service office of t…
  • 2026-11-17 08:01:02
  • Kim Jinsoo
Technology

Lundbeck Maintains Development Plans for AprilBio Co.,Ltd.’s ‘APB-A1’… Concerns Over Technology Return Eased

Danish pharmaceutical company Lundbeck has once again emphasized the potential for multi-indication expansion of its new drug candidate “APB-A1” (Lu AG22515), which it licensed from AprilBio Co.,Ltd.(…
  • 2026-11-17 07:42:03
  • KIM SAE-MI
Lifestyle

Voronoi, Inc.: Effect of VRN10 by Dosage Remains Unclear… Possibility of Further Analysis

Voronoi, Inc.(310210)’s new anticancer drug candidate “VRN10” (VRN101099) demonstrated early antitumor activity by achieving a partial response (PR) in patients with HER2-mutated solid tumors. However…
  • 2026-11-17 07:06:03
  • Kim Jinsoo
Lifestyle

Why Mezion Pharma Co., Ltd. Sold Its Australian Patent for 5.4 Billion… Reduces ‘Legal Losses by 75%’ to Avoid Being Designated a ‘Watch List’ Stock

Mezzion Pharma Co., Ltd.(140410)has taken a calculated risk by selling two Australian patents for udenafil for 5.4 billion won, thereby removing itself from the list of stocks subject to investment ca…
  • 2026-11-17 06:01:02
  • KIM JI-WAN
Business·Industry

Earnings Boost Lunit and DRTECH; Lawsuit Weighs on Curiox [K-Bio Pulse]

Shares of Lunit and DRTECH rose on November 13 as improving financial performance attracted investor interest. Lunit gained on revenue growth and narrowing operating losses, while DRTECH benefited fro…
  • 2026-11-16 07:42:03
  • Kim Jinsoo
1 2 3 4 5 6 7 8 9 10 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English